Choose a condition to see what trials are open for enrollment
Active Enrolling Wet Age-Related Macular Degeneration Clinical Trials
Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD Veena R. Raiji, MD, MPH
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Henry Feng, MD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Henry Feng, MD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.
Active Enrolling Diabetic Retinopathy Clinical Trials
Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.
Active Enrolling Diabetic Macular Edema Clinical Trials
Primary Investigators: Ryan Sabherwal, MD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.
Active Enrolling Epiretinal Membranes Clinical Trials
Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.
Active Enrolling Geographic Atrophy Clinical Trials
Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.Primary Investigators: Mathew W. MacCumber, MD, PhD
Primary Contact: Sara Montgomery
Location: Oak Park
Billing information: All scheduled study visits, testing, procedures, and drug are paid for by the study.
Active Enrolling Inherited Retinal Disease
N/A
Previous Clinical Trial Experience
- VFQ-25 – Visual Function Questionnaire
- AREDS2 – Age-Related Eye Disease Study 2
- CLOVER – Combination Lucentis & OPT with Visudyne with Evaluation-based Treatments
- Alcon AART – Alcon Anecortave Risk Reduction
- AMD – Age-Related Macular Degeneration Chart Review Study
- Alcon Anecortave Acetate
- AREDS – Age-Related Eye Disease Study
- Macugen Injections/de novo lesions – Chart Review Study
- Macugen Injections – Chart Review Study
- Eye Tech Study
- PreView PHP – Preferential Hyperactivity Perimeter
- SST – Submacular Surgery Trials
- VER – Visudyne in Early Retreatment of Exudative ARMD with CNV
- VIM – Visudyne in Minimally Classic CNV from ARMD
- Cabernet Trial – CNV following AMD Treated with Beta Radiation Epiretinal Therapy
- Sailor Study
- CAPT Study – Complications in Age-Related Macular Degeneration Prevention Trial
- CATT – Comparison of Age-Related Macular Degneration Treatment Trials
- AGN–150998 – Abicipar Pegol in Patients with Neovascular AMD
- APL2-GA-305 – Extension Study to Evaluate Long-term Safety of Pegcetacoplan for GA secondary to AMD
- Harbor Study – No previous treatment, Subfoveal Neovascular AMD
- LADDER – Phase II study of Ranibizumab/ subfoveal neovascularization AMD
- Neurotech (NT-503) – Phase II study of NT-503-3 Encapsulated Cell technology compared with Eylea for treatment of recurrent subfoveal CNV secondary to AMD
- ONYX – Phase II study of repeated doses of REGN910-3 for neovascular AMD
- OZONE – Ocriplasmin Pazopanib vs Lucentis for wet AMD
- Ozurdex As Adjunctive Therapy to Lucentis for CNV Secondary to AMD
- Phase II Proof of Concept Study of HuCNS-SC – Subretinal Transplantation for Geographic Atrophy of AMD
- Proxima A – Prospective Epidemiologic Study of the Progression of GA secondary to AMD
- RADIANT – HuCNSSC Subretinal Transplantation for GA of AMD
- REVIEW – Open-label study of Eylea in patients with wet AMD
- Sequoia – Abicipar Pegol in patients with neovascular AMD
- Squalamine – Phase III study of Squalamine for neovascular AMD
- Genetic Screening Study to Evaluate Long-Term Clinical Outcomes/Non-central GA, Carriers of High-Risk Genetic Complement Variants Associated with Dry AMD
- Archway GR40548 – Wet AMD
- Portal GR40549 – Wet AMD
- LUCIA
- SOL/SOL-R
- ELARA
- ASCENT
- ARTEMIS
- AVICEDA
- DAYBREAK
- 4FRONT-1
- 4FRONT-2
- AQUARIUS
- DRCR Protocol I
- DRCR Protocol J
- READ-2 Study – Ranibizumab (Lucentis) alone vs. Combination with Laser for Diabetic Macular Edema
- CDS – Controlled Delivery Study
- DRCR ISI vs. Laser for Diabetic Macular Edema
- DRCR Protocol H – Bevacizumab (Avastin) vs. Laser for DME
- DRCR Protocol H Laser for DME
- DMEVS – Diabetic Macular Edema Vitrectomy Study
- Ranibizumab (Lucentis) for Diabetic Macular Edema
- Allergan DEX PS DDS – DME with Laser vs. Laser alone
- SurModics, Phase II
- FAME Study
- DRCR Protocol R – To assess the effects of NSAIDs on macular retinal volume compared with placebo in eyes with non-central DME
- Boulevard – RO6867461 Administered Intravitreally for DME
- DRCR Protocol AA – Peripheral DR Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time
- DRCR Protocol AC – Randomized Trial of Intravitreous Aflibercept vs Intravitreal Bevacizumab/Central Involved DME
- DRCR Protocol A – Pilot Study of Laser Photocoagulation for DME
- DRCR Protocol T – Comparative Effectiveness Study of Intravitreal Afibercept, Bevacizumab and Ranibizumab for DME
- DRCR Protocol Q – Diabetic Retinopathy Clinical Research Network
- DRCR Protocol S – Ranibizumab + Delayed PRP vs Prompt PRP for PDR
- MacuSight Trial – Phase II study of subconjunctival injections of Sirolimus/DME secondary to diabetic retinopathy
- REINFORCE – Ozurdex in patients diagnosed with DME
- Retisert – Clinical Investigation of Fluocinolone Acetonide Intravitreal Implant for DME
- TIME2B – Subcutaneously Administered AKB-9778 for Moderate to Severe Non-Proliferative DR
- DRCR Protocol Genes – Genes in Diabetic Retinopathy
- The Paladine Study – DR-DME Iluvien
- DRCR Protocol AF – Fenofibrate for Prevention of Diabetic Retinopathy Worsening
- Magnolia Study – CLS-TA for treatment of macular edema/non-infectious uveitis
- ISIS-DME: Intravitreal Steroid Injection Study (ISIS) for Evaluation of Intravitreal Triamcinolone Acetonide for Management of Refractory Clinically Significant Diabetic Macular Edema
- ELARA
- DRCR Protocol AN
- SCORE – Standard Care vs. Corticosteroid for CRVO and BRVO
- CRAVE – CRAVE – Comparison of Avastin vs. Lucentis in the treatment of macular edema following retinal vein occlusion. These are active or past studies which our doctors have served as principal investigators or co-investigators.
- The Humboldt Study by Gilead Sciences, Inc. – Evaluating efficacy and safety of Filgotnib
- SYNCHRONICITY
- OPTYK-1
- CLARITY
-jCYTE